Revascularisation for Peripheral Artery Disease in France: Implications for the Implementation of VOYAGER-PAD

Victor Aboyans; Olivier Morboeuf; Benjamin Grenier; Ronan Jolivel; Alessandra Bura-Riviere

doi:10.1016/j.ejvs.2024.01.091

Revascularisation for Peripheral Artery Disease in France: Implications for the Implementation of VOYAGER-PAD

Eur J Vasc Endovasc Surg. 2024 Feb 3:S1078-5884(24)00118-7. doi: 10.1016/j.ejvs.2024.01.091. Online ahead of print.

Authors

Victor Aboyans¹, Olivier Morboeuf², Benjamin Grenier³, Ronan Jolivel³, Alessandra Bura-Riviere⁴

Affiliations

¹ Department of Cardiology, Dupuytren-2 University Hospital, and EpiMaCT, Inserm 1094/IRD270, Limoges University Hospital, Limoges, France. Electronic address: vaboyans@live.fr.
² Medical Affairs, Bayer HealthCare SAS, La Garenne Colombes, France.
³ Heva, Lyon, France.
⁴ Vascular Medicine Department, Toulouse University Hospital, Toulouse, France.

PMID: 38316351
DOI: 10.1016/j.ejvs.2024.01.091

Abstract

Objective: The VOYAGER-PAD trial demonstrated the interest in dual pathway inhibition (DPI) (low dose rivaroxaban plus aspirin) to reduce limb and cardiovascular events after revascularisation for peripheral artery disease (PAD), but its applicability in clinical practice has not yet been assessed. This study aimed to assess the number of patients revascularised in France for PAD and to estimate the proportion of those matching the VOYAGER-PAD trial selection criteria. A secondary objective was to examine the prognosis of revascularised patients in a real world setting.

Methods: This observational retrospective study was conducted on the national hospital discharge database and included all patients with PAD who underwent lower extremity revascularisation for PAD (without lower extremity revascularisation in the two years prior to inclusion) from 1 January 2016 to 31 December 2019. Available VOYAGER-PAD selection criteria were then applied to the study population.

Results: In total, 180 870 patients were included (mean age 72.0 ± 12.2 years, 30.9% female), with approximately 45 000 patients revascularised annually. Among them, 90 379 (50.0%) matched the VOYAGER-PAD trial criteria (VOYAGER-PAD eligible subgroup; mean age 69.8 ± 12.1 years, 29.5% female). In the study population and the VOYAGER-PAD eligible subgroup, 33.9% and 26.6% of patients had diabetes, 28.1% and 19.9% had chronic coronary artery disease, and 14.6% and 5.7% had renal failure, respectively. Overall, 73.1% of study patients were treated by an endovascular approach (75.5% in the VOYAGER-PAD eligible subgroup). In patients with more than one year of follow up, 45.4% of study patients and 36.0% of the VOYAGER-PAD eligible subgroup experienced a limb or cardiovascular event. The median time until the first event and in hospital death was 4.8 months and 7.8 months, respectively (6.7 months and 12.9 months in the VOYAGER-PAD eligible subgroup).

Conclusion: The burden of PAD for revascularisation and secondary events is considerable. One half of revascularised patients in France are eligible for DPI therapy. Those patients are younger, with fewer comorbidities, and better outcomes.

Keywords: Aspirin; Epidemiology; Peripheral artery disease; Revascularisation prognosis; Rivaroxaban.